問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2023-09-19

王舒儀
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王舒儀

List

58Cases

2023-09-27 - 2026-07-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-06-01 - 2024-10-25

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2024-01-01 - 2025-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2019-08-01 - 2025-02-28

Phase III

Completed
Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Semaglutide Tablets 3 mg / 7 mg / 14 mg

Participate Sites
3Sites

Terminated3Sites

2024-09-30 - 2026-06-30

Phase II

Active
A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    tablets

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-01-01 - 2026-12-31

Phase III

Active
A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD

  • Condition/Disease

    Obesity

  • Test Drug

    BI 456906

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2009-07-01 - 2011-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2018-12-18 - 2021-12-31

Phase III

A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Efpeglenatide

Participate Sites
6Sites

Not yet recruiting6Sites

2008-07-01 - 2010-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2009-10-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB